Abstract
A group of 23 elderly outpatients with dysthymic disorder participated in a 13-week fluoxetine trial. Twelve responders received open continuation treatment and subsequently discontinued fluoxetine (mean: 32 weeks on medication). During the 24 weeks after discontinuation, 6 of the 12 patients relapsed. Clinical features, dose, and duration of fluoxetine treatment were not predictive of relapse. The 50% relapse rate in this small sample is lower than that reported in young adult dysthymic patients but is high enough to warrant clinical caution.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Ambulatory Care
-
Antidepressive Agents, Second-Generation / administration & dosage
-
Antidepressive Agents, Second-Generation / adverse effects*
-
Dose-Response Relationship, Drug
-
Dysthymic Disorder / drug therapy*
-
Dysthymic Disorder / psychology
-
Female
-
Fluoxetine / administration & dosage
-
Fluoxetine / adverse effects*
-
Humans
-
Male
-
Middle Aged
-
Recurrence
-
Risk Factors
-
Single-Blind Method
-
Substance Withdrawal Syndrome / etiology*
Substances
-
Antidepressive Agents, Second-Generation
-
Fluoxetine